Introduction

Taxol, a plant diterpenoid widely used as a chemotherapeutic drug, is known to interact with a specific site of β-tubulin (Manfredi et al., 1982; Rao et al., 1992). It binds to microtubules and inhibits their disassembly (Schiff et al., 1979). Cells treated with taxol are arrested in mitosis and eventually undergo death by apoptosis (Rowinsky and Tolcher, 2001). The ability of taxol and taxotere, another taxane (Fig. 1), to kill tumour cells has made them useful chemotherapeutic agents against several types of cancers, including those derived from ovary, breast, head and neck, and lung as well as malignant melanoma (Rowinsky and Tolcher, 2001).

With respect to taxol and its analogues, numerous structure-activity studies over the past two decades have led to several generalizations, and the most crucial one concerns three key side chains of the molecules: the C-2 benzyl, the C-4 acetyl, and the C-13 side chain moieties (Wang et al., 2007). More than that, both atomic constitution and molecular conformation are critical to taxane-tubulin binding and cytotoxicity (Gueritte, 2001; Kingston, 2001). Especially, the side chain at position C-13 and the taxane ring system have been regarded as essential determinants for the activity of taxol and docetaxel. The isolated side chain and the taxane ring system with its other substituents, exemplified by baccatin III, have generally been considered inactive on mammalian microtubules (Andreu and Barasoain, 2001). Interestingly, the interaction of baccatin III with the taxol-binding site of microtubules determined by a homogeneous assay with fluorescent taxoid showed that the interaction of the C-2 and C-4 substituted taxane ring system with the microtubule binding site provides most of the free energy change of taxol binding and is sufficient to activate microtubule stabilization and transmit the antitumour effects of taxol, whereas the C-13 side chain provides a weak specific anchor (Andreu and Barasoain, 2001). The structure-activity relationship of taxol suggested that groups at C-1, C-7, C-9, and C-10 have weaker effects on its bioactivity, while C-2 benzoyl, C-4 acetyl, the D-ring, and the C-13 side chain have stronger effects on it (Tian et al., 2007). This is the basis for our motivation to investigate the structure-activity relationship of taxol analogues by docking them to the taxol binding site of microtubules. Several molecular docking models of taxol binding have recently been presented, which include extensive contacts of the 2-O-benzoyl and the taxane ring system with several residues in the structure of β-tubulin. In the present work, analysis of taxol analogues bindings suggests that most of the affinities of taxol analogues are contributed to the interactions of the 2-O-benzoyl and taxane ring system with the microtubule binding site, whereas the side chains/groups at positions C-1, C-4, C-7,
C-9, C-10, and C-13 provide only some specific additional bindings.

**Material and Methods**

*Taxol analogues and tubulin*

As shown in Fig. 1, 13 compounds were used in this study: four taxol analogues without a D-ring, two C-4 substituted analogues of taxol, two C-3' substituted taxol analogues, two taxol analogues are C-7 modified compounds; in addition, taxotere (Gueritte et al., 1991) and ortataxel (Baldelli et al., 2004) were involved.

The 3D structures of all these taxol analogues were generated by VI EWDD (http://rcmd-server.frm.uniroma1.it/rcmd-portal/index.php).

The complex of αβ-tubulin with taxol (PDB code: 1jff) was used as the target with an α-tubulin subunit and taxol removed.

The 3D structures minimization of taxol analogues and target protein were conducted by the molecular modeling system UCSF chimera (Pettersen et al., 2004) (http://www.cgl.ucsf.edu/chimera).

**Molecular docking**

AutoDock4 (Morris et al., 1998) was used for automatic placements of taxol analogues in the taxol binding cavity of the target β-tubulin. The target structure was set up using AutoDockTools (Sanner, 1999) for docking by removing all water and ligand atoms, adding polar hydrogen atoms, and assigning AMBER (Ponder and Case, 2003;
Wang et al., 2006) atomic charges and solvation parameters as required by the AutoDock program. In the same way, the chemical structures of taxol analogues were prepared by assigning Gasteiger atomic charges, and rotatable bonds were explicitly defined.

Docking was then carried out using an empirical free energy function and the Lamarckian genetic algorithm. One hundred independent docking runs were performed for each taxol analogue, applying a standard AutoDock protocol, with a grid spacing of 0.375 Å, an initial population of 300 randomly placed individuals, a maximum number of $2.5 \times 10^7$ energy evaluations, a maximum number of 1000 generations, a mutation rate of 0.02, and a crossover rate of 0.80.

The post-processing of docking results was conducted by AutoDockTools (Sanner, 1999) and Dockres (http://atlas.physbio.mssm.edu/~mezei/dockres/dockres.html).

**Results and Discussion**

**Validation of docking pose**

To validate if all taxol analogues docked to the taxol binding site of β-tubulin, the distribution of target protein residues closest to docked taxol analogues was analyzed (as shown in Fig. 2). For each taxol analogue, only the top 5 poses were considered. It is obvious that all taxol analogues docked to the residue His229, which can be the key residue of the taxol binding site on the microtubule (Rao et al., 1999). In addition, Asp26, Pro274, Thr276, Arg278, Arg284, and Gly370, shown in Fig. 2, were involved in direct interactions with taxol and β-tubulin (Lowe et al., 2001). It is worth to note that less taxol analogues docked to residue Arg284 despite it is the key residue of the taxol binding site (Rao et al., 1999). In fact, unlike taxol, not all taxol analogues can interact with β-tubulin well. In a word, the docked residues shown in Fig. 2 suggest that all taxol analogues fitted into the taxol binding site on the target protein.

The correct docking pose is critical to simulate the interactions of taxol analogues with the microtubule binding site. The complex of β-tubulin with taxol and the docking pose with the lowest docking energy are shown in Fig. 3. The two poses in Fig. 3 are compatible with each other on the whole, and the main difference is the slight rotation of the docking pose. As a simulation model, such a pose is acceptable and can be used to analyze the interaction of taxol with the microtubule binding site. In fact, we are able to generally predict the correct binding mode of ligand and receptor with AutoDock.

**Analysis of structure-activity relationship**

Compounds 1–4 are D-ring modified taxol analogues (Fig. 1). In 1, the oxygen atom of the D-ring is substituted by a sulfur atom, and the C-13 side chain and the sulfur atom are not involved in the interactions with β-tubulin. In fact, the sulfur derivative 1 was found to be less active than taxol in biological assays (Gunatilaka et al., 1999). Compound 3 is an open D-ring analogue, and is biologically inactive in an *in vitro* cytotoxicity as-
say and a tubulin assembly assay (Barboni et al., 2001). The C-13 side chain (except for two benzene rings) and ring A did not participate in the interactions with the target. Compound 2 cyclized directly without an oxygen atom in the D-ring, and compound 4, like 3, is an analogue of taxol with D-ring opening. They had been predicted to be nearly as active as taxol in binding to the binding site of tubulin, but all were biologically inactive in an in vitro cytotoxicity assay and a tubulin assembly assay (Barboni et al., 2004; Dubois et al., 2000). Correspondingly, not like 1 and 3, only the C-1 hydroxy, C-9 carbonyl, C-1′ carbonyl, and C-2′ hydroxy groups in 2 and 4 were not involved in the binding with β-tubulin. The results suggest that: (i) the A-ring and C-13 side chain are important for microtubule binding; (ii) the D-ring is essential for microtubule binding and the oxygen atom in the D-ring plays an important role in the mechanism by which taxol exhibits its anticancer activity. In fact, the D-ring is important in determining the taxane ring system conformation (Tian et al., 2007).

Compounds 5 and 6 are analogues of taxol with the C-4 acetyl group substituted by hydroxy or methoxycarbonyl groups, respectively (Fig. 1). The C-4 methoxycarbonyl group in 6 was involved in binding with β-tubulin, and the C-4 hydroxy group was not. Interestingly, the free binding energies of 5 and 6 (−4.5 and −3.9 kcal/mol, respectively) are lower than that of taxol (−3.6 kcal/mol), which means that derivatives 5 and 6 are as active as taxol in binding to tubulin. The results imply that the C-4 acetyl group may not be as important as the D-ring for microtubule binding.

Compounds 7 and 8 are C-3′ substituted (Fig. 1). Compared to 8, all C-3′ phenyl, C-2′ hydroxy, and C-1′ carbonyl groups in the C-13 side chain of derivative 7 did not bind to the target site. In other words, the microtubule binding of derivative 7 is not as well as that of 8. The result was further supported by the free binding energies of 7 and 8 (−3.3 and −4.2 kcal/mol, respectively). Contradictorily, derivative 7 was found to be more potent than taxol in both the tubulin polymerization assay and the in vitro cytotoxicity assay, and derivative 8 was inactive in both assays (Xue et al., 2000). The conflicts suggest that the C-13 side chain may provide specific binding in microtubule binding. For the specific binding of the C-13 side chain, the free binding energies of 7 and 8 are nearly similar to that of taxol.

Compound 9 is a derivative with transposition of the C-7 hydroxy group of taxol to the C-6 posi-
tion. Compound 10 is an analogue of taxol with the C-7 hydroxy group substituted by an ether group. As for 9, C-6 hydroxy, C-9 carbonyl, and C-10 acetyl groups were not involved in microtubule binding, but it was found to be similar to taxol in both the tubulin polymerization assay and the in vitro cytotoxicity assay (Wittman et al., 1999). The result suggested that the groups at positions C-7, C-9, and C-10 are not essential groups for microtubule binding. As for 10, C-1 hydroxy, C-1’ carbonyl, C-4 acetyl, and C-10 acetyl groups did not bind to the target site. Interestingly, the preclinical antitumour activity of 10 was superior to taxol (Altstadt et al., 2001). This suggested that not only the groups at positions C-1, C-4, and C-10 are not essential groups for microtubule binding, but also the proper substitution at these positions, such as C-7, can be helpful to improve the bioactivity of taxol.

In addition, two new-generation taxanes, taxotere and ortataxel, were docked to the taxol binding site of microtubules. Compared to taxol, taxotere was more potent at inhibiting angiogenesis and preferred for clinically treating patients with breast cancer (Crown et al., 2004; Grant et al., 2002). As shown in Fig. 1, taxotere is an analogue of taxol with C-10 acetyl and C-3’ phenylcarbamoyl groups substituted by hydroxy and isobutyl ester groups, respectively. Interestingly, C-1 and C-2’ hydroxy groups were not involved in the microtubule binding. It is to say that the proper substitution at the C-1 and C-13 side chains can improve the bioactivity of taxol. Ortataxel, a taxane derivative with a form of 1,14-carbonate moiety (Fig. 1), exhibits excellent activity against a variety of drug-sensitive and drug-resistant cancer cell lines and is currently in phase II clinical trials (Geney et al., 2005). Especially, it retains encouraging activity and clinical benefit in breast cancer patients who are resistant to taxol or taxotere combinations, and its toxicity, comparable to those of the two other taxanes, was tolerable in heavily treated population (Beer et al., 2008).

It is worth to note that C-4 acetyl, C-9 carbonyl, and C-1’ carbonyl groups were not involved in the interactions with ortataxel and β-tubulin. This suggested further that C-4 and C-9 groups are not essential groups for microtubule binding, and the 1,14-carbonate moiety can improve the pharmacological properties such as a better bioavailability.

Finally, we can draw the following conclusions: (1) the C-2 benzoyl group, involved in the interactions with all taxol analogues and β-tubulin, and taxane ring system are essential for microtubule binding; (2) the substituents at positions C-1, C-4, C-7, C-9, C-10, and C-14 can improve the bioavailability and activity spectrum; (3) despite it is important for microtubule binding, the C-13 side chain mainly provides a specific binding.

Acknowledgements

This work was funded by China Postdoctoral Science Foundation (No. 20080430978).


Grant D. S., Williams T. L., Zahaczewsky M., and Dicker A. P. (2002), Comparison of antiangiogenic activities
using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer 104, 121–129.


